POSITIVE IMPACT OF TRANEXAMIC ACID IN VARIOUS MEDICAL SETTINGS

Katarzyna Herjan; Piotr Armański; Jakub Olszewski; Magdalena Sitnik; Maciej Bara

doi:10.56782/pps.248

Data publikacji : 2024-09-24

Tom 22 Nr 3 (2024)

POSITIVE IMPACT OF TRANEXAMIC ACID IN VARIOUS MEDICAL SETTINGS

Katarzyna Herjan

Piotr Armański

Jakub Olszewski

Magdalena Sitnik

Maciej Bara

DOI: https://doi.org/10.56782/pps.248

Abstrakt

The role of successful hemostasis cannot be overemphasized. Bleeding can occur due to various reasons and its cause is not always evident. Any delay in restoring the proper hemostasis is associated with increased risk of complications and therefore results in increased mortality. Discovered in 1962 by Japanese researchers Shosuke and Utako Okamoto, tranexamic acid (TXA) is an anti-fibrinolytic agent that inhibits plasminogen activation by blocking the lysine binding sites on plasminogen. Thanks to its ability to inhibit fibrinolysis it stabilizes the preformed fibrin mesh-work and has a beneficial effect in reducing blood loss in wide range of clinical settings. TXA has been shown to reduce the risk of perioperative bleeding in patients undergoing noncardiac surgeries. CRASH trials provided the largest body of evidence confirming effectiveness of early administration of TXA, defined as administration within 3 hours after trauma, in reducing mortality in patients with severe injuries and traumatic brain injury. Recent evidence indicates that TXA administration in treatment of postpartum hemorrhage results in notable mortality reduction. Topical or locally injected tranexamic acid may reduce blood loss and improve visibility of the surgical field. More high-quality studies are needed to determine safety, efficacy and dosage. The risk of serious adverse events, especially vascular occlusive events, in patients receiving TXA compared to placebo group did not differ significantly.

Słowa kluczowe:

tranexamic acid, antifibrinolytic agents, bleeding, trauma

Inne teksty tego samego autora

Katarzyna Kozon, Małgorzata Krzyżanowska, Jakub Olszewski, Andrzej Patyra, Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland , Prospects in Pharmaceutical Sciences: Tom 21 Nr 2 (2023)
Jakub Olszewski, Katarzyn Kozon, Andrzej Patyra, Flozins in heart failure – a new reimbursement indication , Prospects in Pharmaceutical Sciences: Tom 20 Nr 1 (2022)
Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Tom 22 Nr 1 (2024)
Maciej Bara, Agata Janczak, Toxicity of anesthetic gases: exposure in operating rooms and influence on the environment. , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patyra, Efficacy of satralizumab therapy in the treatment of NMOSD , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
Maciej Bara, Jakub Starownik, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański, Dapagliflozin - new solution in chronic kidney disease treatment , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
Jakub Olszewski, Katarzyna Kozon, Magdalena Sitnik, Katarzyna Herjan, Karolina Mikołap, Bartłomiej Gastoł, Maciej Bara, Piotr Armański, Marcin Sawczuk, Mirikizumab – a new option in treatment of inflammatory bowel diseases , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)

Podobne artykuły

Dariusz Łaszczych, Aleksandra Czernicka, Kornelia Kędziora-Kornatowska, Interaction between warfarin and selected superfoods: a comprehensive review of potential mechanisms and their clinical significance , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)

<< < 1 2 3 4 5

Możesz również Rozpocznij zaawansowane wyszukiwanie podobieństw dla tego artykułu.

Szczegóły

Bibliografia

Statystyki

Autorzy

Pobierz pliki

PDF

Zasady cytowania

Herjan, K., Armański, P., Olszewski, J., Sitnik, M., & Bara, M. (2024). POSITIVE IMPACT OF TRANEXAMIC ACID IN VARIOUS MEDICAL SETTINGS. Prospects in Pharmaceutical Sciences, 22(3), 204–209. https://doi.org/10.56782/pps.248

Wskaźniki altmetryczne

Cited by / Share

Licencja

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa 4.0 Międzynarodowe.

Bibliografia

Ausen, K.; Fossmark, R.; Spigset, O.; Pleym, H. Safety and Efficacy of Local Tranexamic Acid for the Prevention of Surgical Bleeding in Soft-Tissue Surgery: A Review of the Literature and Recommendations for Plastic Surgery. Plast. Reconst. Surg. 2022, 149 (3), 774–787. DOI: 10.1097/prs.0000000000008884 DOI: https://doi.org/10.1097/PRS.0000000000008884

Scarafoni, E. A Systematic Review of Tranexamic Acid in Plastic Surgery: What’s New? PRS Global Open 2021, 9 (3), e3172. DOI: 10.1097/GOX.0000000000003172 DOI: https://doi.org/10.1097/GOX.0000000000003172

Murkin, J. M. Lessons Learned in Antifibrinolytic Therapy: The BART Trial. Semin. Cardiothorac. Vasc. Anesth. 2009, 13 (2), 127–131. DOI: 10.1177/1089253209338076 DOI: https://doi.org/10.1177/1089253209338076

Ker, K.; Prieto-Merino, D.; Roberts, I. Systematic Review, Meta-Analysis and Meta-Regression of the Effect of Tranexamic Acid on Surgical Blood Loss. Br. J. Surg. 2013, 100 (10), 1271–1279. DOI: 10.1002/bjs.9193 DOI: https://doi.org/10.1002/bjs.9193

Henry, D. A.; Carless, P. A.; Moxey, A. J.; O’Connell, D.; Stokes, B. J.; Fergusson, D. A.; Ker, K. Anti-Fibrinolytic Use for Minimising Perioperative Allogeneic Blood Transfusion. Cochrane Database Syst. Rev. 2011. DOI: 10.1002/14651858.cd001886.pub3 DOI: https://doi.org/10.1002/14651858.CD001886.pub3

Franchini, M.; Mannucci, P. M. The Never Ending Success Story of Tranexamic Acid in Acquired Bleeding. Haematol. 2020, 105 (5), 1201–1205. DOI: 10.3324/haematol.2020.250720 DOI: https://doi.org/10.3324/haematol.2020.250720

Charakterystyka produktu leczniczego EXACYL (Kwas Traneksamowy) [accesed and cited 01.07.2024]. Available: from: https://rejestry.ezdrowie.gov.pl/api/rpl/medicinal-products/2331/characteristic.

Cai, J.; Ribkoff, J.; Olson, S.; Raghunathan, V.; Al‐Samkari, H.; DeLoughery, T. G.; Shatzel, J. J. The Many Roles of Tranexamic Acid: An Overview of the Clinical Indications for TXA in Medical and Surgical Patients. Eur. J. Haematol. 2019, 104 (2), 79–87. DOI: 10.1111/ejh.13348 DOI: https://doi.org/10.1111/ejh.13348

Devereaux, P. J.; Marcucci, M.; Painter, T. W.; Conen, D.; Lomivorotov, V.; Sessler, D. I.; Chan, M. T. V.; Borges, F. K.; Martínez-Zapata, M. J.; Wang, C. Y.; Xavier, D.; Ofori, S. N.; Wang, M. K.; Efremov, S.; Landoni, G.; Kleinlugtenbelt, Y. V.; Szczeklik, W.; Schmartz, D.; Garg, A. X.; Short, T. G. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N. Engl. J. Med. 2022. 386(21), 1986-1997 DOI: 10.1056/nejmoa2201171 DOI: https://doi.org/10.1056/NEJMoa2201171

Marcucci, M.; Painter, T. W.; Conen, D.; Leslie, K.; Lomivorotov, V. V.; Sessler, D.; Chan, M. T. V.; Borges, F. K.; Martínez Zapata, M. J.; Wang, C. Y.; Xavier, D.; Ofori, S. N.; Landoni, G.; Efremov, S.; Kleinlugtenbelt, Y. V.; Szczeklik, W.; Schmartz, D.; Garg, A. X.; Short, T. G.; Wittmann, M. Rationale and Design of the PeriOperative ISchemic Evaluation-3 (POISE-3): A Randomized Controlled Trial Evaluating Tranexamic Acid and a Strategy to Minimize Hypotension in Noncardiac Surgery. Trials 2022, 23 (1). DOI: 10.1186/s13063-021-05992-1 DOI: https://doi.org/10.1186/s13063-021-05992-1

Grocott, M. P. W.; Murphy, M.; Roberts, I.; Sayers, R.; Toh, C.-H. Tranexamic Acid for Safer Surgery: The Time Is Now. Br. J. Anaesth. 2022, 129 (4), 459–461. DOI: 10.1016/j.bja.2022.06.024 DOI: https://doi.org/10.1016/j.bja.2022.06.024

Shehata, N.; Forster, A.; Lawrence, N.; Rothwell, D. M.; Fergusson, D.; Tinmouth, A.; Wilson, K. Changing Trends in Blood Transfusion: An Analysis of 244,013 Hospitalizations. Transfusion 2014, 54 (10pt2), 2631–2639. DOI: 10.1111/trf.12644 DOI: https://doi.org/10.1111/trf.12644

Dewan, Y.; Komolafe, E. O.; Mejía-Mantilla, J. H.; Perel, P.; Roberts, I.; Shakur, H. CRASH-3 - Tranexamic Acid for the Treatment of Significant Traumatic Brain Injury: Study Protocol for an International Randomized, Double-Blind, Placebo-Controlled Trial. Trials 2012, 13 (1). DOI: 10.1186/1745-6215-13-87 DOI: https://doi.org/10.1186/1745-6215-13-87

Roberts, I.; Belli, A.; Brenner, A.; Chaudhri, R.; Fawole, B.; Harris, T.; Jooma, R.; Mahmood, A.; Shokunbi, T.; Shakur, H. Tranexamic Acid for Significant Traumatic Brain Injury (the CRASH-3 Trial): Statistical Analysis Plan for an International, Randomised, Double-Blind, Placebo-Controlled Trial. Wellcome Open Res. 2018, 3, 86. DOI: 10.12688/wellcomeopenres.14700.2 DOI: https://doi.org/10.12688/wellcomeopenres.14700.1

The CRASH-3 trial collaborators. Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled Trial. The Lancet 2019, 394 (10210), 1713–1723. DOI: 10.1016/s0140-6736(19)32233-0 DOI: https://doi.org/10.1016/S0140-6736(19)32233-0

Koh, A.; Adiamah, A.; Gomez, D.; Sanyal, S. Safety and efficacy of tranexamic acid in minimizing perioperative bleeding in extrahepatic abdominal surgery: meta-analysis. BJS Open 2021, 5 (2). DOI: 10.1093/bjsopen/zrab004 DOI: https://doi.org/10.1093/bjsopen/zrab004

Mansukhani, R.; Frimley, L.; Shakur-Still, H.; Sharples, L.; Roberts, I. Accuracy of Time to Treatment Estimates in the CRASH-3 Clinical Trial: Impact on the Trial Results. Trials 2020, 21 (1). DOI: 10.1186/s13063-020-04623-5 DOI: https://doi.org/10.1186/s13063-020-04623-5

Oyelese, Y.; Scorza, W. E.; Mastrolia, R.; Smulian, J. C. Postpartum Hemorrhage. Obstet. Gynecol. Clin. North. Am. 2007, 34 (3), 421–441. DOI: 10.1016/j.ogc.2007.06.007 DOI: https://doi.org/10.1016/j.ogc.2007.06.007

Shakur, H.; Elbourne, D.; Gülmezoglu, M.; Alfirevic, Z.; Ronsmans, C.; Allen, E.; Roberts, I. The WOMAN Trial (World Maternal Antifibrinolytic Trial): Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind Placebo Controlled Trial. Trials 2010, 11 (1). DOI: 10.1186/1745-6215-11-40 DOI: https://doi.org/10.1186/1745-6215-11-40

Updated WHO Recommendation on Tranexamic Acid for the Treatment of Postpartum Haemorrhage [accesed and cited 01.07.2024]. Available from: https://iris.who.int/bitstream/handle/10665/259379/WHO-RHR-17.21-eng.pdf.

Myles, P. S.; Smith, J. A.; Forbes, A.; Silbert, B.; Jayarajah, M.; Painter, T.; Cooper, D. J.; Marasco, S.; McNeil, J.; Bussières, J. S.; McGuinness, S.; Byrne, K.; Chan, M. T. V.; Landoni, G.; Wallace, S. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N. Engl. J. Med. 2017, 376 (2), 136–148. DOI: 10.1056/nejmoa1606424 DOI: https://doi.org/10.1056/NEJMoa1606424

Shi, J.; Zhou, C.; Liu, S.; Sun, H.; Wang, Y.; Yan, F.; Pan, W.; Zheng, Z. Outcome Impact of Different Tranexamic Acid Regimens in Cardiac Surgery with Cardiopulmonary Bypass (OPTIMAL): Rationale, Design, and Study Protocol of a Multicenter Randomized Controlled Trial. Am. Heart J. 2020, 222, 147–156. DOI: 10.1016/j.ahj.2019.09.010 DOI: https://doi.org/10.1016/j.ahj.2019.09.010

Katarzyna Herjan

katarzyna_herjan@icloud.com

Afiliacja:

Center of Postgraduate Medical Education, Prof. W. Orłowski Memorial Hospital, 00-401 Warsaw, Poland Poland

Piotr Armański

Afiliacja:

District Hospital in Sochaczew, 96-500 Sochaczew, Poland Poland

Jakub Olszewski

Afiliacja:

Masovian Brodnowski Hospital, 03-242 Warsaw, Poland Poland

Magdalena Sitnik

Afiliacja:

Masovian Brodnowski Hospital, 03-242 Warsaw, Poland Poland

Maciej Bara

Afiliacja:

Infant Jesus Clinical Hospital, Medical University of Warsaw, 02-005 Warsaw, Poland Poland